National Conference of Hellenic Sepsis Study Group

The pandemic caused by the new coronavirus SARS-CoV-2 (disease COVID-19) was the springboard for the emergence of the Greek Sepsis Study Group as a protagonist of international therapeutic developments in the treatment of patients with serious infections. After the authorization of the drug anakinra for the treatment of adults with COVID-19 pneumonia by the European Medicines Agency, a similar authorization was given in November 2022 by the Food and Drug Administration agency of the United States of America. Licensing is based on the results of phase II and III studies SAVE and SAVE-MORE. This success led to international recognition of our Group’s leadership in the development of precision therapeutic strategies for critically ill patients.
This two-day event must now evolve into a conference that is not limited to scientific information on current scientific developments, but where the conduct of clinical trials is taught in a holistic way. The goal is to teach all of us, doctors, nurses, biologists and pharmacists, how uniting and using the principles that brought us success will make our vision a reality: the cure from sepsis and the improvement of the quality of life of our patients.